肺腺癌中PLK1的异常表达及其临床病理意义-东南大学学报医学版

肺腺癌中PLK1的异常表达及其临床病理意义

单位：1. 东南大学医学院病理与病理生理学系, 江苏南京 210009;
2. 解放军杭州疗养院特勤疗养科, 浙江杭州 310007;
3. 南京总医院病理科, 江苏南京 210002

分类号：R741.02

出版年·卷·期（页码）：2017·36·第五期（804-810）

摘要：

目的：探讨肺腺癌中PLK1的异常表达及临床病理意义。方法：免疫组化SP法检测266例I-IV期肺腺癌中PLK1的表达并分析其与临床病理特征、预后、TTF1和p53表达及分子学表型的关系。结果：PLK1过表达与吸烟（P<0.05）、转移/复发（P<0.01）及高临床分期（P<0.05）显著相关。常见于胶样腺癌（87.5%）、浸润性黏液腺癌（86.7%）和实体型腺癌（81.1%）（P<0.01）。在泌黏液型腺癌（73.1%）中发生率显著高于非泌黏液型腺癌（57.5%）（P<0.05）。PLK1过表达与KRAS突变、p53表达及三阴性肺腺癌显著相关（P<0.01），与TTF1表达、EGFR突变和EML4-ALK融合基因无显著相关性。肺腺癌中PLK1过表达与预后相关（P<0.01）且为独立预后因素（HR=2.235，P<0.01）。结论：PLK1过表达在部分肺腺癌的发病和进展过程中发挥重要作用。

Objective:To explore the abnormal expression and the clinicopathologic significance of Polo-like kinase 1 (PLK1) in adenocarcinoma (ADC) of the lung. Methods:The expressions of PLK1 in 266 patients with stage I-IV lung ADC were detected by immunohistochemistry (IHC) (SP method). The correlations with PLK1 expression and the clinicopathological characteristics, the expression of TTF1 and p53 and the molecular phenotype were further analyzed. Results:There was a positive correlation with PLK1 overexprssion and smoking history (P<0.05), metastesis/recurrence (P<0.01), and higher stage (P<0.05). PLK1 overexpression was more frequently found in colloid ADCs (87.5%), invasive mucinous ADCs (86.7%) and solid ADCs (81.1%) (P<0.01). PLK1 overexprssion was more common in mucin-product ADCs than in non mucin-product ADCs (P<0.05). PLK1 overexpression was significiantly correlated with KRAS mutation (P<0.01), p53 protein expression (P<0.01) and triple negative ADCs (P<0.01), other than TTF1 expression, EGFR mutation or EML4-ALK fusion. In lung ADCs, PLK1 overexpression was strongly associated with prognosis (P<0.01), and played as an independent prognostic role (HR=2.235, P<0.01). Conclusion:PLK1 overexpression possibly plays an important role in pathogenesis and evolution of a subset of lung ADCs.

参考文献：

[1] GUTTERIDGE R E,NDIAYE M A,LIU X,et al.PLK1 inhibitors in cancer therapy:from laboratory to clinics.Mol Cancer Ther.2016,15(7):1427-1435.
[2] ELLIS P M,CHU Q S,LEIGHL N,et al.A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.Clin Lung Cancer.2013,14(1):19-27.
[3] SEBASTIAN M,RECK M,WALLER C F,et al.The efficacy and safety of BI 2536,a novel Plk-1 inhibitor,in patients with stage ⅢB/IV non-small cell lung cancer who had relapsed after,or failed,chemotherapy:results from an open-label,randomized phase Ⅱ clinical trial[J].J Thorac Oncol,2010,5(7):1060-1067.
[4] TRAVIS W D,BRAMBILLA E,BRUKE A P,et al.WHO classification of tumours of the lung, pleura, thymus and heart[M].Lyon:IARC Press,4th Edition,2015:1-104.
[5] RUSCH V W,APPLEMAN H D,BLACKSTONE E,et al.Lung.In:Edge S B,Byrd D R,Compton C C,et al,eds.AJCC Cancer staging manual 7th edn.American Joint Commision on Cancer[M].Chicago:Springer; 2009:253-270.
[6] KADOTA K,YRH Y C,D'ANGELO S P,et al.Associations between mutations and histologic patterns of mucin in lung adenocarcinoma:invasive mucinous pattern and extracellular mucin are associated with KRAS mutation[J].Am J Surg Pathol,2014,38(8):1118-1127.
[7] YATABE Y.EGFR mutations and the terminal respiratory unit[J].Cancer Metastasis Rev,2010,29(1):23-36.
[8] SUMIYOSHI S,YOSHIZAWA A,SONOBE M,et al.Non-terminal respiratory unit type lung ADC has three distinct subtypes and is associated with poor prognosis[J].Lung Cancer,2014,84(3):281-288.
[9] POSCH C,CHOLEWA B D,VUJIC I,et al.Combined inhibition of MEK and Plk1 has synergistic antitumor activity inNRAS mutant melanoma[J].J Invest Dermatol,2015,135(10):2475-2483.
[10] WATANABE G,ISHIDA T,FURUTA A,et al.Combined immunohistochemistry of PLK1,p21,and p53 for predicting TP53 status:An independent prognostic factor of breast cancer[J].Am J Surg Pathol,2015,39(8):1026-1034.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录